Central Venous Catheter-Related Infection
Launched by UNIVERSITY OF WITWATERSRAND, SOUTH AFRICA · Sep 21, 2007
Trial Information
Current as of May 05, 2025
Completed
Keywords
ClinConnect Summary
Intravascular devices are an integral component of modern-day medical practice. They are used to administer intravenous fluids, medications, blood products and parenteral nutrition. In addition, they serve as a valuable monitor of the hemodynamic status of critically ill patients.
Infection is one of the leading complications of intravascular catheters and is associated with an increased mortality, prolonged hospitalization and increased medical costs. Central venous catheters(CVCs) account for an estimated 90% of all catheter-related bloodstream infections(CRBSI). A host of risk factors f...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • critically ill patients likely to require central venous catheter for at least 14 days
- • age 18+ years
- • white cell count on admission \> 4 x 10 to 9/L
- • absence of skin burns
- • no history of allergy to sulfa containing preparations
- • consent obtained
- • catheter to be inserted via internal jugular or subclavian veins
- Exclusion Criteria:
- • age \< 18 years
- • white blood cell count on admission of less than 4 x 10 to 9/L
- • skin burns
- • history of allergy to sulfa-containing preparations
- • guidewire changes
About University Of Witwatersrand, South Africa
The University of Witwatersrand (Wits), located in Johannesburg, South Africa, is a leading research institution renowned for its commitment to advancing healthcare through innovative clinical trials and research initiatives. With a strong emphasis on interdisciplinary collaboration, Wits leverages its expertise in various medical fields to address critical health challenges in both local and global contexts. The university's clinical trials are designed to generate robust evidence that informs clinical practices and health policies, ultimately contributing to improved patient outcomes. Wits is dedicated to ethical research conduct and fostering partnerships with stakeholders, ensuring that its studies uphold the highest standards of scientific integrity and social responsibility.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Mervyn Mer, MBBChFCP(SA)
Principal Investigator
Department of Medicine, Division of Pulmonology and Critical Care, Johannesburg Hospital and University of the Witwatersrand, Johannesburg, South Africa
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials